Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.48 |
| ▸ | NPY1R | P25929 | 6/20 | 0.48 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | GLP1R | P43220 | 4/20 | 0.47 |
| ▸ | SCTR | P47872 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645278 | 0.95 | GLP1R (0.47) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645274 | 0.94 | GLP1R (0.48) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645272 | 0.94 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645275 | 0.94 | GLP1R (0.44) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645268 | 0.93 | C5AR1 (0.42) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645277 | 0.91 | GLP1R (0.48) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645276 | 0.91 | GLP1R (0.48) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30645281 | 0.91 | GLP1R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL30823264 | 0.91 | APLNR (0.50) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL6710584 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | Bomi LLC (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11860174-B2 | Anti-cannabidiol antibody and uses thereof | CNR2, CNR1, MAG | NPY4R 1058/4885NPY1R 1503/4885NPY2R 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.